Stock EFTR EFFECTOR THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News eFFECTOR Therapeutics, Inc.

Equities

EFTR

US28202V2079

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
1.89 USD +4.42% Intraday chart for eFFECTOR Therapeutics, Inc. +11.18% -83.83%
Apr. 04 Health Care Down on Retreat From Risk -- Health Care Roundup DJ
Apr. 04 Top Midday Decliners MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Health Care Down on Retreat From Risk -- Health Care Roundup
DJ
Top Midday Decliners
MT
EFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
AQ
EFFECTOR Therapeutics, Inc. Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
CI
Top Premarket Decliners
MT
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
Transcript : EFFECTOR Therapeutics, Inc. - Special Call
EFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
AQ
EFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
AQ
Transcript : EFFECTOR Therapeutics, Inc. - Special Call
EFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024
GL
EFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024
AQ
EFFECTOR Therapeutics Announces Reverse Stock Split
GL
EFFECTOR Therapeutics Announces Reverse Stock Split
AQ
EFFECTOR THERAPEUTICS ANNOUNCES NEW POSITIVE INTERIM DATA FROM DOSE ESCALATION AND PHASE 2 EXPANSION COHORTS OF ZOTATIFIN IN ER+ METASTATIC BREAST CANCER PATIENTS
AQ
EFFECTOR Therapeutics Says Study of Zotatifin in Breast Cancer Patients Yields 'Positive' Interim Data
MT
EFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients
GL
EFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients
AQ
EFFECTOR Therapeutics, Inc. Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Er+ Metastatic Breast Cancer Patients
CI
EFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast Cancer
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EFTR Stock
  4. News eFFECTOR Therapeutics, Inc.